Compare GTN & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GTN | TBPH |
|---|---|---|
| Founded | 1897 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 468.6M | 993.7M |
| IPO Year | N/A | N/A |
| Metric | GTN | TBPH |
|---|---|---|
| Price | $5.31 | $18.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $7.60 | ★ $27.80 |
| AVG Volume (30 Days) | ★ 1.1M | 516.8K |
| Earning Date | 11-07-2025 | 11-10-2025 |
| Dividend Yield | ★ 6.02% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.43 | ★ 0.58 |
| Revenue | ★ $3,348,000,000.00 | $80,327,000.00 |
| Revenue This Year | N/A | $70.78 |
| Revenue Next Year | $13.42 | N/A |
| P/E Ratio | ★ $12.36 | $31.31 |
| Revenue Growth | N/A | ★ 27.12 |
| 52 Week Low | $2.91 | $7.90 |
| 52 Week High | $6.31 | $20.33 |
| Indicator | GTN | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 59.88 | 54.58 |
| Support Level | $4.57 | $17.25 |
| Resistance Level | $4.87 | $20.32 |
| Average True Range (ATR) | 0.22 | 0.73 |
| MACD | 0.08 | -0.28 |
| Stochastic Oscillator | 77.92 | 30.62 |
Gray Media Inc is a multimedia company. The company owns and operates local television stations and digital assets. It also owns Gray Digital Media, a full-service digital agency offering national and local clients digital marketing strategies with digital products and services. Its additional media properties include video production companies Raycom Sports, Tupelo Media Group, and PowerNation Studios, and studio production facilities Assembly Atlanta and Third Rail Studios.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).